This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech

Lifting of Cuba Sanctions Could Be Bonanza for U.S. Companies

  • Tickers in this article:
  • PBR

Companies involved in mining, petroleum exploration, agribusiness, biotechnology and tourism may benefit.

12/17/14 - 03:43 PM EST

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know

To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.

12/17/14 - 09:20 AM EST

Auspex Drug Reduces Uncontrolled Movements in Huntington's Patients

Auspex Drug Reduces Uncontrolled Movements in Huntington's Patients

Auspex is expected to seek U.S. approval for SD-809 next year.

12/16/14 - 04:06 PM EST

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.

12/16/14 - 11:20 AM EST

2014's Worst CEO Nominees in the Biotechnology Industry

The nominees are in for this year's Worst CEO in Biotech.

12/15/14 - 01:54 PM EST

Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015

Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015

With 2014 nearly over, the question now becomes which stocks, sectors and strategies billionaire investors will be betting on in 2015. A few predictions.

12/15/14 - 09:27 AM EST

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?

12/15/14 - 11:49 AM EST

IEA Cuts 2015 Forecast for Oil Demand; Oil lower; Baidu stake in Uber

Oil is front and center this month, while Merck is facing some headwinds

12/12/14 - 07:33 AM EST

Former Onyx CEO Returns to Biotech to Launch Boston Start Up

Former Onyx CEO Returns to Biotech to Launch Boston Start Up

  • Tickers in this article:
  • AMGN

Tony Coles, the former CEO of Onyx sold to Amgen for $10 billion in late 2013, is launching Yumanity Therapeutics focused on developing drugs for neuro-degenerative diseases.

12/15/14 - 09:23 AM EST

DBV Technologies CEO: Peanut Allergy Patch Propelling Stock

DBV Technologies CEO: Peanut Allergy Patch Propelling Stock

  • Tickers in this article:
  • DBVT

DBV Technologies profile in the U.S. has risen along with its stock since the French biotech went public in October, said the company's CEO Dr. Pierre-Henri Benhamou.

12/10/14 - 04:57 PM EST

The Nominees for Best Biotechnology Co. CEO of 2014 Are...

The Nominees for Best Biotechnology Co. CEO of 2014 Are...

The CEOs of Exact Sciences, Idenix Pharma, Prosensa, Agios, Bluebird Bio and InterMune vie for the coveted title of Best Biotech CEO

12/12/14 - 06:05 AM EST

Merck Checkpoint Inhibitor Shows Activity in Hard-to-Treat Form of Breast Cancer

Merck Checkpoint Inhibitor Shows Activity in Hard-to-Treat Form of Breast Cancer

  • Tickers in this article:
  • MRK

Five of 27 patients with an aggressive and hard-to-treat form of breast cancer responded to treatment with Merck's checkpoint inhibitor Keytruda.

12/10/14 - 09:21 AM EST

Cramer Dubs Bluebird Bio a 'Winner' but Says to Avoid Conn's

Cramer Dubs Bluebird Bio a 'Winner' but Says to Avoid Conn's

Jim Cramer says Bluebird Bio's presentation at the American Society of Hematology was very impressive, but Conn's earnings report has too many questions marks.

12/09/14 - 11:11 AM EST

Bluebird Gene Therapy Inducing Durable Cures in Blood Disorder Patients

Bluebird Gene Therapy Inducing Durable Cures in Blood Disorder Patients

  • Tickers in this article:
  • BLUE

Beta-thalassemia patients no longer require blood transfusions following a single treatment with Bluebird's LentiGlobin gene therapy.

12/08/14 - 05:45 PM EST

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs